Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150913 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
A Phase 2 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04150913 is a Phase 2 study that has completed, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 15 participants.
The verdict
NCT04150913, a Phase 2 study, has completed, sponsored by Marcela V. Maus, M.D.,Ph.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL). * Relapsed NHL is the condition of returned Non-Hodgkin lymphoma. * Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma. * Cytokine Release Syndrome (CRS) is a group of side effect symptoms that can include nausea, headache, rapid heartbeat, shortness of breath, kidney damage, and rash. * Neurologic toxicity is nervous system disorder characterized by confusion This research study involves two drugs: * Anakinra * Axicabtagene Ciloleucel.
Interventions
- DRUG Anakinra
- DRUG Axicabtagene Ciloleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150913
The ClinicalTrials.gov registry entry for NCT04150913 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marcela V. Maus, M.D.,Ph.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anakinra is the first listed.
NCT04150913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04150913 about?
NCT04150913 is a clinical study titled "A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity". This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL). * Relapsed NHL is the condition of returned Non-Hodg...
What is the current status of trial NCT04150913?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-10-01. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT04150913?
The interventions under investigation include: Anakinra (DRUG), Axicabtagene Ciloleucel (DRUG).
Who is sponsoring clinical trial NCT04150913?
This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.